Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups
Introduction - The phase III RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma (ENDEAVOR) trial showed significantly improved progression-free survival and overall survival (OS) with carfilzomib (56 mg/...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2 May 2019
|
| In: |
Clinical lymphoma, myeloma & leukemia
Year: 2019, Jahrgang: 19, Heft: 8, Pages: 522-530.e1 |
| ISSN: | 2152-2669 |
| DOI: | 10.1016/j.clml.2019.04.018 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.clml.2019.04.018 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S215226501930028X 
|
| Verfasserangaben: | Robert Z. Orlowski, Philippe Moreau, Ruben Niesvizky, Heinz Ludwig, Albert Oriol, Wee Joo Chng, Hartmut Goldschmidt, Zhao Yang, Amy S. Kimball, Meletios Dimopoulos |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1688141987 | ||
| 003 | DE-627 | ||
| 005 | 20240404193216.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200123s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clml.2019.04.018 |2 doi | |
| 035 | |a (DE-627)1688141987 | ||
| 035 | |a (DE-599)KXP1688141987 | ||
| 035 | |a (OCoLC)1341299028 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Orlowski, Robert Z. |e VerfasserIn |0 (DE-588)1203319363 |0 (DE-627)1688141553 |4 aut | |
| 245 | 1 | 0 | |a Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma |b updated overall survival, safety, and subgroups |c Robert Z. Orlowski, Philippe Moreau, Ruben Niesvizky, Heinz Ludwig, Albert Oriol, Wee Joo Chng, Hartmut Goldschmidt, Zhao Yang, Amy S. Kimball, Meletios Dimopoulos |
| 264 | 1 | |c 2 May 2019 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 23.01.2020 | ||
| 520 | |a Introduction - The phase III RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma (ENDEAVOR) trial showed significantly improved progression-free survival and overall survival (OS) with carfilzomib (56 mg/m2) and dexamethasone (Kd56) versus bortezomib and Kd56 (Vd) in patients with relapsed or refractory multiple myeloma (RRMM). We report updated OS and safety data after 6 months of additional follow-up. - Patients and Methods - Patients with RRMM (1-3 previous lines of therapy) were randomized 1:1 to Kd56 or Vd. Median OS was estimated using the Kaplan-Meier method; OS was compared between treatment groups using Cox proportional hazards models. - Results - As of July 19, 2017, median follow-up was 44.3 months for Kd56 and 43.7 months for Vd. Median OS was 47.8 months (Kd56) versus 38.8 months (Vd; hazard ratio, 0.76; 95% confidence interval, 0.633-0.915). OS was longer with Kd56 versus Vd within age and cytogenetic subgroups, and according to number of previous lines of therapy, previous bortezomib exposure, previous lenalidomide exposure, and lenalidomide-refractory status. Exposure-adjusted incidences per 100 patient-years of adverse events (AEs) were 1352.07 for Kd56 and 1754.86 for Vd; for Grade ≥3 AEs, these values were 162.31 and 175.90. - Conclusion - With median follow-up of approximately 44 months, clinically meaningful improvements in OS were observed with Kd56 versus Vd, including in all subgroups examined. The Kd56 safety profile was consistent with previous analyses. | ||
| 650 | 4 | |a Clinical outcomes | |
| 650 | 4 | |a Efficacy | |
| 650 | 4 | |a Phase III | |
| 650 | 4 | |a Proteasome inhibitor | |
| 700 | 1 | |a Moreau, Philippe |e VerfasserIn |0 (DE-588)1095523767 |0 (DE-627)856146544 |0 (DE-576)463046390 |4 aut | |
| 700 | 1 | |a Niesvizky, Ruben |e VerfasserIn |0 (DE-588)1023118777 |0 (DE-627)717709515 |0 (DE-576)366420615 |4 aut | |
| 700 | 1 | |a Ludwig, Heinz |e VerfasserIn |0 (DE-588)1078703272 |0 (DE-627)83916565X |0 (DE-576)451629620 |4 aut | |
| 700 | 1 | |a Oriol, Albert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chng, Wee Joo |e VerfasserIn |0 (DE-588)105690447X |0 (DE-627)794217338 |0 (DE-576)412904799 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Yang, Zhao |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kimball, Amy S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dimopoulos, Meletios A. |e VerfasserIn |0 (DE-588)111795188X |0 (DE-627)871747634 |0 (DE-576)479413746 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lymphoma, myeloma & leukemia |d Amsterdam [u.a.] : Elsevier, 2010 |g 19(2019), 8, Seite 522-530.e1 |h Online-Ressource |w (DE-627)620142014 |w (DE-600)2540998-0 |w (DE-576)358408776 |x 2152-2669 |7 nnas |a Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma updated overall survival, safety, and subgroups |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g number:8 |g pages:522-530.e1 |g extent:10 |a Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma updated overall survival, safety, and subgroups |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.clml.2019.04.018 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S215226501930028X |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200123 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 999 | |a KXP-PPN1688141987 |e 357914314X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma","title_sort":"Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma","subtitle":"updated overall survival, safety, and subgroups"}],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"2 May 2019"}],"note":["Gesehen am 23.01.2020"],"id":{"doi":["10.1016/j.clml.2019.04.018"],"eki":["1688141987"]},"physDesc":[{"extent":"10 S."}],"name":{"displayForm":["Robert Z. Orlowski, Philippe Moreau, Ruben Niesvizky, Heinz Ludwig, Albert Oriol, Wee Joo Chng, Hartmut Goldschmidt, Zhao Yang, Amy S. Kimball, Meletios Dimopoulos"]},"relHost":[{"language":["eng"],"part":{"year":"2019","pages":"522-530.e1","text":"19(2019), 8, Seite 522-530.e1","issue":"8","volume":"19","extent":"10"},"titleAlt":[{"title":"Clinical lymphoma, myeloma and leukemia"}],"note":["Gesehen am 04.02.20"],"origin":[{"publisherPlace":"Amsterdam [u.a.] ; Dallas, Tex.","dateIssuedDisp":"2010-","dateIssuedKey":"2010","publisher":"Elsevier ; CIG Media Group"}],"pubHistory":["10.2010 -"],"title":[{"title_sort":"Clinical lymphoma, myeloma & leukemia","title":"Clinical lymphoma, myeloma & leukemia"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma updated overall survival, safety, and subgroupsClinical lymphoma, myeloma & leukemia","recId":"620142014","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["620142014"],"zdb":["2540998-0"],"issn":["2152-2669"]}}],"recId":"1688141987","person":[{"display":"Orlowski, Robert Z.","family":"Orlowski","given":"Robert Z.","role":"aut"},{"given":"Philippe","role":"aut","family":"Moreau","display":"Moreau, Philippe"},{"family":"Niesvizky","display":"Niesvizky, Ruben","given":"Ruben","role":"aut"},{"given":"Heinz","role":"aut","display":"Ludwig, Heinz","family":"Ludwig"},{"given":"Albert","role":"aut","family":"Oriol","display":"Oriol, Albert"},{"role":"aut","given":"Wee Joo","display":"Chng, Wee Joo","family":"Chng"},{"role":"aut","given":"Hartmut","family":"Goldschmidt","display":"Goldschmidt, Hartmut"},{"display":"Yang, Zhao","family":"Yang","role":"aut","given":"Zhao"},{"family":"Kimball","display":"Kimball, Amy S.","role":"aut","given":"Amy S."},{"given":"Meletios A.","role":"aut","family":"Dimopoulos","display":"Dimopoulos, Meletios A."}],"language":["eng"]} | ||
| SRT | |a ORLOWSKIROCARFILZOMI2201 | ||